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PRIMED AND BOOSTED ANTI-BREAST CANCER TUMOR IMMUNITY AFTER
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT):
IN VIVO PRIMING WITH T CELLS ARMED WITH ANTI-CD3 X ANTI-
HER2/NEU BISPECIFIC ANTIBODY (HER2BI) PRE PBSCT AND BOOSTING
AFTER PBSCT WITH ACTIVATED T CELLS (ATC)
Lum, L.G.1,2, Thakur, A.1, Al-Kadhimi, Z.1, Abidi, M.1, Ayash, L.1,
Cummings, F.3, Rathore, R.3, Uberti, J.P.1, Ratanatharathorn, V.1 1Kar-
manos Cancer Institute and Wayne State University, Detroit, MI;
2Wayne State University, Detroit, MI; 3Roger Williams Medical Center,
Rhode Island, RI
Innovative treatment strategies are needed for women with meta-
static breast cancer. In a phase I immunotherapy (IT) trial, infusions
of ATC armed with anti-CD3 x anti-Her2/neu bispecific antibody
(Her2Bi) induced specific cytotoxicity (SC) in the peripheral blood
lymphocytes (PBL) directed at SK-BR-3 breast cancer cells. Armed
ATC induced high levels of Th1 cytokines and IL-12 in the serum
of patients. After IT, we obtained memory T cells by leukopheresis,
expanded the T cells, and re-infused the T cells after PBSCT to
test the hypothesis that the transfer of immuneTcellswould reconsti-
tute anti-tumor activity after PBSCT. This primeand post-PBSCT
boostwas performed in 5 patients. In the primingpart of the approach,
all patients received 8 infusions of armed ATC. Approximately 3
weeks after the armed ATC infusions, patients underwent a second
leukopheresis for the generation ofATC, and leukopheresis to collect
stem cells. The expanded ATC from 5 patients at an effector:target
ratio (E/T) of 25:1 exhibited specific cytotoxicity (SC) ranging
from3.7-25.8 (mean5 13.6%)directed at theSK-BR-3breast cancer
cell line. Phenotyping of the cell products from the patients after
armed ATC therapy revealed a mean of 50.2% (25-74 range) CD4+
cells, 30.4% (16.3-51.3) CD8+ cells, 11.6% (4.5-24.3) CD56 +
CD16+ cells, and 29.5% (10.4-41) CD4 +CD25+ cells. Two weeks
after PBSCT, the mean proportions of CD4+ and CD8+ cells were
55.5 and 17.7%, respectively. After HDC and PBSCT, 5 evaluable
patients received multiple infusions with a mean total of 54 billion
ATC (range 16-110 billion). All Cr release assays were done an E:T
of 25:1. Multiple doses of ATC were infused after PBSCT. Pt 1 ex-
hibited SC of 69 and 4.7% at 2 and 4 weeks, respectively, after
PBSCT. Pt 2 exhibited 73, 36, 12, and 10% SC at 0.5, 1, 7, and 18
months. Pt 3 exhibited 26, 21, 14, 37, 24, and 29% SC at 0.5, 1, 2,
3, 6, and 12 months. Pt 4 exhibited 28, 6, and 3% SC at 0.5 and
1 month. Pt 5 exhibited background levels of SC at 0.5 and 1 months
after PBSCT. There was no cytotoxicity directed at Daudi targets.
Several patients exhibited high levels of NK activity directed at
K562 cells early after PBSCT. These data show that transfer of
pre-immunized ATC and T cells in the stem cell product enhance
tumor specific cytotoxicity after HDC and PBSCT for breast cancer.
This pre-boost strategy with targeted T cells may well be applicable
to other tumors and hematologic disorders.31
CNS REMISSION PREDICTS SURVIVAL AFTER AUTOLOGOUS HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (AHCT) FOR NON-HODGKIN LYM-
PHOMA (NHL) WITH PRE-EXISTING CNS INVOLVEMENT: A CIBMTR
ANALYSIS
Maziarz, R.T.1, Wang, Z.2, Zhang, M.-J.3, Laport, G.G.4,
Lazarus, H.M.5, Montoto, S.6, Hari, P.N.2 1Oregon Health & Science
University, Portland, OR; 2Center for International Blood and Marrow
Transplant Research, Medical College of Wisconsin, Milwaukee, WI;
3Medical College of Wisconsin, Milwaukee, WI; 4Stanford Hospital &
Clinics, Stanford, CA; 5University Hospitals Case Medical Center, Cleve-
land, OH; 6Queen Mary – University of London, London, United King-
dom
Previous, retrospective single institutional and registry analyses
have suggested that pre-existing central nervous system (CNS)
involvement was not a contraindication for AHCT for patients
with non-Hodgkin lymphoma (NHL). We analyzed the outcomes
of 151 (64% male) adult recipients of AHCT with NHL and CNS
involvement identified at any time prior to transplant and compared
them to 4688 AHCT with no CNS lymphoma involvement during
the years 1990-2005. Median follow-up of survivors was 77 months.
Significant baseline differences were noted between the groups.
Patients with pre-existingCNS lymphomamore likely to be youngerat transplant, with lower performance status and higher age adjusted
international prognostic index scores. A greater proportion of
patients in the cohort with CNS involvement had advanced stage
at diagnosis, more aggressive histology and increased number of
extranodal sites. They also had a shorter interval between diagnosis
and transplantation. No significant differences in sex, B or T cell
phenotype, B symptoms at diagnosis, bonemarrow involvement dur-
ing the course of disease, number of prior lines of therapy, condition-
ing regimens, or disease status at transplantation were observed
between cohorts. Cumulative incidences of outcomes and univariate
probabilities of disease-free survival (DFS) and overall survival (OS)
at five years are summarized in table 1. No statistically significant dif-
ferences in non-relapse mortality (NRM), relapse, DFS or OS were
identified between the two groups. Patients withCNS remission (96/
151) at time of AHCT had significantly superior survival compared
with those with active CNSdisease (55/151) at transplant (Table 1B).
Significantly higher relapse rates with an associated diminished DFS
and OS (3 year OS 31%) were found in patients with active disease.
Excellent long-term survival is possible after AHCT in NHL pa-
tients with prior CNS involvement despite adverse baseline prognos-
tic factors. However, best outcomes are in patients who achieve
a CNS remission prior to transplant.Table 1A. Outcomes at 5 Years Post AHCT
Non-CNS CNS P-valueRelapse 57% 61% 0.075
NRM 8% 9% 0.756
OS 49% 42% 0.079
DFS 35% 30% 0.127Table 1B: Pre-transplant CNS Status Impacts Outcomes 3 Years
Post AHCTRemission Active P-valueRelapse 49% 72% \0.001
NRM 5% 9% 0.099
OS 58% 31% \0.001
DFS 46% 19% \0.001GRAFT PROCESSING
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A NOVEL METHOD OF GENETICALLY ENGINEERED K562 CELLS TO SIG-
NIFICANTLY EXPAND CORD BLOOD (CB) NK CELLS AND INCREASE CB
NK RECEPTOR EXPRESSION AND NK CELL ACTIVATION
Hochberg, J.1, Ayello, J.2, van de Ven, C.2, Baxi, L.3, Zhao, F.1,
Cairo, M.2,4,5 1New York Medical College, Maria Fareri Children’s Hos-
pital, Valhalla, NY; 2Columbia University, Morgan Stanley Children’s
Hospital of New York-Presbyterian, NY; 3Columbia University, Morgan
Stanley Children’s Hospital of New York-Presbyterian, NY; 4Columbia
University, Morgan Stanley Children’s Hospital of New York-Presbyter-
ian, NY; 5Columbia University, Morgan Stanley Children’s Hospital,
New York-Presbyterian, NY
NK cells play a role in reducing relapse in hematological malig-
nancy following AlloSCT (Dunbar et al, Haematologica, 2008). NK
cells limitations include lack of tumor recognition and limited NK
cell numbers (Shereck et al, Ped Bld Can, 2007). To circumvent this,
PB MNCs activation/expansion with genetically engineered K562
cells expressing membrane bound IL-15 and 41BB ligand (K562-
mbIL15-41BBL; Imai/Campana et al, Blood, 2005) have shown to
be increased in number and maintain heterogeneous KIR expression
(Fusaki et al BJH, 2009). CBNK cells can be activated, expanded and
exhibit enhanced cytolytic activity when cultured with antibody/
cytokines (Ayello/Cairo et al,ExpHeme, 2009).We sought to develop
an improved NK expansion system for potential ACI strategies by
comparing CB NK expansion/activation, characterization and NK
cytolytic activation following stimulation with K562-mbIL15-
41BBL (generously supplied by D.Campana, St Jude’s Children’s
Hospital, Memphis, TX). Following 100 Gy irradiation, K562-
mbIL15-41BBL or WTK562 cells were incubated 1:1 with CB
Oral Presentations S167MNCs for 7d in RPMI-1640 + 10 IU IL-2. NKR expression
(KIR2DS4, NKG2D, NKG2A, CD94, KIR3DL1, KIR3DL2,
Nkp46), LAMP-1 receptor expression and NK cell phenotype
(CD56dim/bright subsets) determined by flow cytometry. On Day 0,
CD3-/56+ NK cell subset was 3.06 1.3%. After 7d culture, NK cells
increased to 71.76 3.9%, compared tomedia alone (9.76 2.4%) and
WTK562 (42.66 5.9%,p\0.01). This represented a 35-fold or
33746 385% increase of input NK cell number. CB Tcells were
decreased compared to media alone and WTK562 (15.16 1.7 vs
516 7.1 vs 35.76 2.4%,p\0.001). CD56bright vs CD56dim subsets
were increased (67 vs 33%,p\0.01) following K562-mbIL15-
41BBL stimulation. CB NK cells expressing KIR3DL1 were
increased 10-fold following stimulation with K562-mbIL15-41BBL
vsWTK562 (p\0.01) and 5-fold increase in NK KIR2DS4 expres-
sion (p\0.05), respectively. NK activation marker, CD107a was in-
creased compared to WTK562 (516 0.7 vs 326 1.1%, p\0.05).
Since a standard cryopreserved UCB unit contains approximately
75107 MNCs, by using the smaller aliquot (5 ml or 20%)
150106 MNCs x 3.9%5 5.8106NK cells, this method may yield
2.0108 CB NK cells after 7d culture. This suggests that CBMNC
can be expanded by K562-mbIL15-41BBL resulting in increased
NK cell KIR expression (KIR2DS4, KIR3DL1) and NK activation
(CD107a) with a decrease in T cells which may provide a means to
enhance specific CB NK expansion for ACI in post UCBT setting.33
VIABILITY AND POTENCY OF HEMATOPOIETIC PROGENITOR CELLS AF-
TER PROLONGED CRYOPRESERVATION AT -80 C
Khattab, M., Gilmore, G.L., Sahovic, E.A., Miller, S.M., Rossetti, J.M.,
Abdulhaq, H., Lister, J. The Western Pennsylvania Cancer Institute,
Pittsburgh, PA
Hematopoietic progenitor cell (HPC) products cryopreserved in
the liquid or vapor phase of liquid nitrogen (LN) remain viable
and potent for years. Cryopreserved HPC products when stored at
-80 C inmechanical freezers are known to remain viable and potent
for up to 180 days. We demonstrated viability and potency of HPC
products stored at -80 C for up to 12 years. Products were cryopre-
served in 6% hydroxyethyl starch, 5%DMSO and 4% human serum
albumin using non-controlled rate freezing.
Thawed products were tested for viability and potency respec-
tively by trypan blue dye exclusion and hematopoietic progenitor
cell colony assay (CFU-GM, BFU-E, CFU-GEMM). All culture as-
says used MethoCult GF+ H4445 (STEMCELL Technologies,
Vancouver, BC, Canada).
We thawed 20HPC products collected frommobilized peripheral
blood. The products were stored between 7 and 12 years at -80 C.
In 19 cases, trypan blue dye exclusion yielded an average 72% viabil-
ity (range: 50%-89%). HPC colony assay yielded average progenitor
frequencies of: CFU-GM159 [range: 15-600]; BFU-E 116 [range: 2-
388] and CFU-GEMM 21 [range: 2-68] all per 105 viable cells
plated. The average values did not differ from control values of
CFU-GM 111, BFU-E 121 and CFU-GEMM 23. Two products
were infused into their donors after myeloablative conditioning,
UPN947 andUPN1000. The products were stored for over 9 years.
The products fromUPN947/UPN1000 gave 73%/65%viability by
trypan blue dye exclusion, CFU-GM 347/508, BFU-E 135/344,
CFU-GEMM 12/48 per 105 viable cells, ANC500 day + 14/
day + 11 and PLT50 day + 15/day + 24.
We conclude that viability and potency of these HPC products
flash-frozen and stored at -80 C in pentastarch is maintained for
up to 12 years. In two cases engraftment was achieved with long-
term cryopreserved products. The data suggest that prolonged cryo-
preservation of HPC products using LN may not be necessary to
preserve product potency.
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DEVELOPMENT OF THE ‘‘MARROWMINER’’: A NOVEL, MINIMALLY INVA-
SIVE DEVICE OF FOR THE HARVEST OF BONE MARROW. FROM BENCH-
TOP, TO ANIMAL STUDIES, THROUGH FDA APPROVAL AND HUMAN
EVALUATION
Kraft, D.1, Crocker, M.2, Ghazarossian, V.2, Antonio, C.A.3 1Stanford
University, Stanford, CA; 2StemCor Systems Inc,Menlo Park, CA; 3San-
gre De Cordon SA, Guadalajara, MexicoBonemarrow (BM) is the traditional graft source in hematopoietic
stem cell transplantation. An increasing body of work suggests that
use of BM grafts may show long-term advantages over mobilized
PBSC in some alloegeneic transplant settings, resulting in signifi-
cantly less cGVHD, morbidity and improved survival. Traditional
OR based BM harvest methods however remain crude, labor and re-
source intensive, generally requiring full general anesthesia, 2 trans-
plant clinicians, 100+ serial small volume needle aspirates, and result
in grafts highly diluted by peripheral blood. Improved harvest
methods are needed.
To address the need to develop improved methods for harvest,
The ‘‘MarrowMiner’’ (MM) was conceived. The MarrowMiner
(MM), is a novel, now FDA cleared & CE-Marked device developed
for the minimally invasive harvest of BM to enable the rapid, conve-
nient, outpatient harvest of large quantities of BM via a single mar-
row entry site, under local anesthesia. A powered, rotating FlexShaft
enables the clinician to access a broad area of the ileac marrow space
through a single cortical bone entry site trocar. The FlexShaft moves
through the cancellous bone, without puncturing the cortical wall,
while aspirating rich marrow under negative pressure into a closed
container.
Preclinical trails in porcine models compared the marrow har-
vested with the MM to standard 6-hole harvest in the opposite ileac.
This 6 pig study revealed a significantly richer bonemarrow with.9
foldColony Forming (CFU-F) perml compared to standard harvest.
Following FDA approval, successful ‘First in Man’ studies were con-
ducted demonstrating safety and efficacy in patients having marrow
harvested for regenerative medicine studies.
A 21 patient trial comparing the MM to standard harvest. The
MARVELOUS (MARrowMiner VErsus standard ILeac bOne
marrow pUncture and aSpiration)) study found that MM aspirate
(performed under local anesthesia) had a greater average TNC
count/ml compared to standard marrow harvest in the same patient,
with equivalent viability. Higher numbers of %ALDH+, CD34+,
phenotypic MSC) were obtained by MM.
The novel MM system demonstrated safety and efficacy in
clinical use. An ongoing trial is evaluating the MM in the BMT set-
ting, and a commercial version of the device is nearing production.
The MM device device may benefit ease of harvest for donors,
clinicians and could ultimately lead to better outcomes for trans-
plant recipients.35
DETECTION AND EX VIVO EXPANSION OF DORMANT ANTI-VIRAL CTL
PRECURSORS ISOLATED FROM RECIPIENTS OF UNRELATED UMBILICAL
CORD BLOOD TRANSPLANT (UCBT)
Marti, L.C.1, Leen, A.M.2, Janetzki, S.3, Baker, J.H.1, Szabolcs, P.4
1Duke University Medical Center, Durham, NC; 2Baylor College of
Medicine, Houston, TX; 3Zellnet Consulting, Fort Lee, NJ; 4Duke Uni-
versity Medical Center
Viral infections are commonly detected within weeks after UCBT
that could trigger in vivo priming of the infused naı¨ve T cells. This
hypothesis is supported by the observation that infections can resolve
without antiviral therapy.
Objectives: In this study we focused on two potentially fatal viruses,
CMV and adenovirus to assess the acquisition and evolution of anti-
gen-specific immunity. We hypothesized that 1) threshold numbers
of CTL precursors can be identified for each virus that may influence
outcome 2) CTL precursors may reside below the level of detection
duringGVHDprophylaxis, however, ex vivo restimulation could ex-
pand them to measurable frequencies.
Methods: Monocytes infected with an adenovirus vector carrying
the CMV pp65 transgene (Ad5f35pp65) were used as APC in the
presence of IL7. Antiviral CTLp was quantitated by ELISPOT
with computerized enumeration of IFNg producing spot forming
cells (SFC) in response to peptide pools spanning dominant viral an-
tigens: hexon and penton for adenovirus, pp65, EI-1 for CMV.
Results: 8 infected patients at a median age of 9.9 years have been
studied. Blood was drawn at a median of 70 days (range 34-470).
Only 1 of 3 patients with adenovirus infection (stool x1, urine x1,
respiratory tract x 1) had associated viremia while all five (5) patients
withCMVhadviremia.Analyzing freshlydrawnperipheral blood1of
